DIFICID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIFICID (DIFICID).
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
| Metabolism | Fidaxomicin is minimally metabolized; hydrolysis of the macrocyclic ring occurs in the gastrointestinal tract, with little systemic metabolism. CYP3A4 is not significantly involved. |
| Excretion | Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor). |
| Half-life | 11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing. |
| Protein binding | 92% to 96% (mainly to albumin). |
| Volume of Distribution | 8.8 to 12.5 L/kg (indicating extensive tissue distribution, especially into intestinal mucosa). |
| Bioavailability | Oral: ~2% (absorbed, but systemic exposure low; primarily acts locally in gut). |
| Onset of Action | Not applicable orally; clinical response observed within 72 hours of initiating therapy. |
| Duration of Action | Treatment course is 10 days; bacteriostatic effect persists while drug concentrations exceed MIC for C. difficile. |
| Molecular Weight | 1058.04 |
200 mg (tablet) orally twice daily for 10 days.
| Dosage form | FOR SUSPENSION |
| Renal impairment | No dose adjustment required for any degree of renal impairment, including hemodialysis. |
| Liver impairment | No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh A, B, or C). |
| Pediatric use | Approved for pediatric patients ≥6 months of age: 200 mg (tablet) or 200 mg/100 mL oral suspension (5 mg/mL) twice daily for 10 days. Weight-based dosing: 10 mg/kg (max 200 mg per dose) orally twice daily for 10 days. |
| Geriatric use | No dose adjustment required based on age. Monitor renal function and electrolytes if concomitant use of diuretics or NSAIDs; otherwise, same as adult dosing. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. Animal studies have shown no evidence of harm at doses up to 16 times the human dose based on AUC. However, use only if clearly needed. |
| 2nd trimester | No known risk in animal studies, but human data are lacking. Use only if potential benefit justifies potential risk to the fetus. |
| 3rd trimester | Similar to T2, no known risk, but caution is advised due to limited human data. |
Clinical note
Comprehensive clinical and safety monograph for DIFICID (DIFICID).
| Placental transfer | Based on its molecular weight (approximately 1058 Da), some placental transfer is expected, but no human data are available. Animal studies show low transfer (less than 1% of maternal levels). |
| Breastfeeding | It is not known whether fidaxomicin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DIFICID is administered to a nursing woman. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to fidaxomicin or any component of the formulation
| Precautions | Hypersensitivity reactions including angioedema have been reported, Not effective for systemic infections due to minimal absorption, Monitor for development of antimicrobial resistance, Use with caution in patients with severe hepatic impairment (Child-Pugh C) due to lack of data |
| Food/Dietary | No clinically significant food interactions. Can be taken with or without food. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Limited data - probably compatible, but caution advised) |
| Teratogenic Risk | DIFICID (fidaxomicin) is not teratogenic in animal studies at doses up to 10 times the human exposure based on AUC. No adequate human studies in pregnancy; FDA Category B. Risk cannot be ruled out for first trimester, but potential benefits may warrant use in pregnant women for severe C. difficile infection. |
| Fetal Monitoring | No specific monitoring required beyond standard C. difficile infection management. Monitor for diarrhea resolution, adverse effects (nausea, vomiting, abdominal pain), and signs of C. difficile recurrence. |
| Fertility Effects | No human studies on fertility. Animal studies up to 2000 mg/kg/day did not demonstrate impaired fertility or reproductive performance. No known effects on human fertility. |
| DIFICID (fidaxomicin) is minimally absorbed systemically, achieving high fecal concentrations. It is bactericidal against Clostridioides difficile and has a narrower spectrum than vancomycin, preserving normal gut flora. Use for initial or recurrent C. difficile infection (CDI) when vancomycin or metronidazole are not preferred. Avoid in patients with hypersensitivity to fidaxomicin. Monitor for clinical response; treatment failure or early recurrence may require alternative therapy. |
| Patient Advice | Take DIFICID exactly as prescribed, usually twice daily for 10 days. · Complete the full course even if you feel better. · Take with or without food. · DIFICID works only against C. difficile; it does not treat other infections. · Do not stop or change dose without consulting your doctor. · Inform your doctor if you are pregnant, breastfeeding, or have kidney/liver problems. · Report any severe or persistent diarrhea, abdominal pain, or blood in stool. · Store at room temperature, away from moisture and heat. |